It assumes that in addition to proliferative reaction to the presence of (at least initially soluble) Aβ by the T cells (of AD patients only) specifically expressing Aβ-specific TCR, the amyloid is recognized (and reacted to) differently by the CD4+CD28+ but not CD4+CD28− cells of high and low responders. The gene discussed is CD28; the disease is Alzheimer disease.